Glioblastoma Clinical Trials in New York, NY

Glioblastoma Clinical Trials in New York, NY

View the best 10 glioblastoma medical studies in New York, New York. Access promising new therapies by applying to a New York-based Glioblastoma clinical trial.

Trials in New York, New York

Here are the top 10 medical studies for glioblastoma in New York, New York

Image of University of Southern California in Los Angeles, United States.

Perillyl alcohol

Monoterpene

Recruiting1 awardPhase 1 & 2
This trial is testing NEO100, a purified form of perillyl alcohol, to treat aggressive brain tumors in patients whose cancer has returned or not responded to other treatments. The treatment is given through the nose regularly and may help slow down tumor growth. Perillyl alcohol (POH) is a naturally occurring substance with properties that may inhibit tumor growth, and NEO100 is a highly purified version of POH currently being tested for glioblastoma treatment.
Image of Children's Hospital of Alabama in Birmingham, United States.

Selpercatinib

Tyrosine Kinase Inhibitor

Recruiting1 awardPhase 2
This trial will test how well selpercatinib works in treating patients with advanced solid tumors, lymphomas, or histiocytic disorders that have activating RET gene alterations.
Image of City of Hope Comprehensive Cancer Center LAO in Duarte, United States.

Selinexor +1 More

Selective Inhibitor of Nuclear Export

Recruiting1 awardPhase 1 & 2
This trial tests selinexor with temozolomide for patients whose brain cancer has returned. Selinexor blocks a protein that helps cancer cells grow, and temozolomide damages their DNA to kill them or stop their growth. Temozolomide is a DNA methylating drug currently used as a first-line treatment in glioblastoma therapy.
Image of City of Hope ( Site 0002) in Duarte, United States.

Pembrolizumab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 2
This trial will test a combination of two drugs to see if it is safe and effective for treating various types of cancer.
Image of Phoenix Childrens Hospital in Phoenix, United States.

Dabrafenib +1 More

Kinase Inhibitor

Recruiting3 awardsPhase 4
This trial is studying the effects of two cancer medications, dabrafenib and trametinib, in children. These drugs work by stopping signals that make cancer cells grow. Dabrafenib and trametinib have shown benefits in various BRAF-mutant tumors, including melanoma, lung cancer, and thyroid cancer. The goal is to see how these treatments affect children over time.
Image of University Health Network Princess Margaret Cancer Center LAO in Toronto, Canada.

Erdafitinib

Kinase Inhibitor

Recruiting1 awardPhase 2
This trial will test a drug (erdafitinib) to see if it can help slow/shrink IDH-WT gliomas with an abnormal FGFR protein.
Image of University of Alabama at Birmingham in Birmingham, United States.

VAL-083 +7 More

Alkylating agents

Recruiting1 awardPhase 2 & 3
This trial is testing various treatments for patients with newly diagnosed or returning brain cancer. It adjusts treatments based on how well patients are doing to find the most effective options. The goal is to improve survival rates by matching the best treatments to specific patient types.
Image of Princess Margaret Cancer Center in Toronto, Canada.

RO7428731

Monoclonal Antibodies

Recruiting1 awardPhase 1
This trial tests a new drug, RO7428731, for safety and effectiveness in patients with a specific type of brain cancer (glioblastoma) that has a particular mutation. The drug works by targeting and binding to the mutated cancer cells to stop their growth. This mutation is common in glioblastoma and makes the cancer grow faster and resist standard treatments.
Image of Odette Cancer Centre, Sunnybrook Health Sciences Centre in Toronto, Canada.

Dose escalation + Reduced Margin Adaptive Radiotherapy

Radiation

Recruiting1 awardPhase 2
This trial is testing if giving higher radiation doses than usual over a shorter time period combined with technology to adapt to tumour dynamics can improve survival rates in elderly GBM/Grade 4 astrocytoma patients.
Image of Northwestern University in Evanston, United States.

Clindamycin Phosphate

Recruiting1 awardPhase 2
This trial will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects for people being treated with Tumor Treating Fields for malignant glioma.

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.